Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SaliCept is an oral wound dressing developed by Carrington Laboratories, Inc., primarily used for the management of mouth sores, oral irritations, and alveolar osteitis (dry socket) following tooth extraction. Its active component is acemannan hydrogel, a polydispersed acetylated mannan derived from the inner gel of the *Aloe vera* L. plant. SaliCept is available as a freeze-dried pledget (patch) or a mucosal coating rinse suspension. It functions as a physical barrier to protect the wound site from further irritation while providing a moist environment conducive to healing. The product received FDA 510(k) clearance as a medical device and has demonstrated clinical efficacy in reducing the incidence of dry socket compared to standard treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SaliCept.